129 related articles for article (PubMed ID: 8476774)
1. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.
Schieweck K; Bhatnagar AS; Batzl C; Lang M
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):633-6. PubMed ID: 8476774
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in rats.
Iino Y; Karakida T; Sugamata N; Andoh T; Takei H; Takahashi M; Yaguchi S; Matsuno T; Takehara M; Sakato M; Kawashima S; Morishita Y
Anticancer Res; 1998; 18(1A):171-6. PubMed ID: 9568073
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
Nishino Y; Schneider MR; Michna H; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):435-7. PubMed ID: 2533949
[TBL] [Abstract][Full Text] [Related]
4. The role of estrogen in the feedback regulation of follicle-stimulating hormone secretion in the female rat.
Bhatnagar AS; Batzl C; Häusler A; Nogués V
J Steroid Biochem Mol Biol; 1993 Dec; 47(1-6):161-6. PubMed ID: 8274431
[TBL] [Abstract][Full Text] [Related]
5. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.
Bhatnagar AS; Häusler A; Schieweck K; Lang M; Bowman R
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1021-7. PubMed ID: 2149502
[TBL] [Abstract][Full Text] [Related]
6. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.
De Coster R; Van Ginckel RF; Callens MJ; Goeminne NK; Janssens BL
Cancer Res; 1992 Mar; 52(5):1240-4. PubMed ID: 1737385
[TBL] [Abstract][Full Text] [Related]
7. Antitumor and endocrine effects of an aromatase inhibitor (CGS 16949A) on DMBA-induced rat mammary tumor.
Houjou T; Wada T; Yasutomi M
Clin Ther; 1993; 15(1):137-47. PubMed ID: 8458043
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
Iino Y; Sugamata N; Owada S; Tago T; Sato H; Yokoe T; Maemura M; Morishita Y; Horiuchi R
Jpn J Clin Oncol; 1991 Jun; 21(3):153-9. PubMed ID: 1834875
[TBL] [Abstract][Full Text] [Related]
9. Endocrine and antitumoral effects of R76713 in rats.
De Coster R; Van Ginckel R; Wouters W; Goeminne N; Vanherck W; Byloos M
J Enzyme Inhib; 1990; 4(2):159-67. PubMed ID: 2098522
[TBL] [Abstract][Full Text] [Related]
10. A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors.
Zaccheo T; Giudici D; Lombardi P; di Salle E
Cancer Chemother Pharmacol; 1989; 23(1):47-50. PubMed ID: 2491793
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
Tanaka M; Yano S; Hasegawa Y; Nakao K
Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
Li S; Lévesque C; Geng CS; Yan X; Labrie F
Breast Cancer Res Treat; 1995 May; 34(2):147-59. PubMed ID: 7647332
[TBL] [Abstract][Full Text] [Related]
13. Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.
Van Ginckel R; Janssens B; Callens M; Goeminne N; Wouters L; De Coster R
Cancer Chemother Pharmacol; 1996; 38(1):21-8. PubMed ID: 8603447
[TBL] [Abstract][Full Text] [Related]
14. The effect of aromatase inhibitor 4-hydroxyandrostenedione on steroid receptors in hormone-dependent tissues of the rat.
Zhou JL; Brodie A
J Steroid Biochem Mol Biol; 1995 Jan; 52(1):71-6. PubMed ID: 7857875
[TBL] [Abstract][Full Text] [Related]
15. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat.
Sinha S; Kaseta J; Santner SJ; Demers LM; Bremmer WJ; Santen RJ
Breast Cancer Res Treat; 1998 Mar; 48(1):45-51. PubMed ID: 9541188
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz(a)anthracene-induced mammary tumors of rat.
Yamamoto T; Urabe M; Tamura T; Kitawaki J; Honjo H; Okada H
Anticancer Res; 1991; 11(6):1999-2002. PubMed ID: 1776832
[TBL] [Abstract][Full Text] [Related]
17. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours.
Zaccheo T; Giudici D; Ornati G; Panzeri A; di Salle E
Eur J Cancer; 1991; 27(9):1145-50. PubMed ID: 1835626
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384.
Nishino Y; Schneider MR; Michna H
J Cancer Res Clin Oncol; 1994; 120(5):298-302. PubMed ID: 8126059
[TBL] [Abstract][Full Text] [Related]
20. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
Schieweck K; Bhatnagar AS; Matter A
Cancer Res; 1988 Feb; 48(4):834-8. PubMed ID: 2962734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
